A Tool to Predict Tuberculosis Drug Resistance Now Available Online
By LabMedica International staff writers Posted on 09 Jun 2015 |
Image: Mycobacterium tuberculosis (stained purple) in a tissue specimen (blue) (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
A new online tool for the rapid analysis of whole genome sequence data is set to aid clinicians predict whether a particular patient's tuberculosis (TB) will be susceptible to frequently prescribed antibiotics.
The World Health Organization (WHO) estimated that 5% of the world's 11 million tuberculosis patients have multi-drug-resistance disease (MDR-TB) and that 480,000 new cases arose during 2013 alone. Of those approximately 9% have extensively resistant tuberculosis (XDR-TB) where, in addition to resistance to at least both of the major first line drugs (isoniazid and rifampicin), they also have resistance to two classes of second line drugs used to treat MDR-TB (the fluoroquinolones and the injectable drugs, amikacin, kanamycin, or capreomycin).
Current molecular tests examine limited numbers of mutations in Mycobacterium tuberculosis, the organism that causes TB, and although whole genome sequencing could fully characterize drug resistance, the complexity of data obtained by this technology has restricted their clinical application.
To help solve this problem investigators at the London School of Hygiene & Tropical Medicine (United Kingdom) have created an online tool that analyses and interprets genome sequence data to predict resistance to 11 drugs used for the treatment of TB. Initially, a library (1,325 mutations) predictive of drug resistance for 15 anti-tuberculosis drugs was compiled and then validated for 11 of them using genomic-phenotypic data from 792 strains. A rapid online "TB-Profiler" tool was developed to report drug resistance and strain-type profiles directly from raw sequences. The TB-Profiler tool is available on the Internet (Please see Related Links below).
Senior author Dr. Taane Clark, reader in genetic epidemiology and statistical genomics at the London School of Hygiene & Tropical Medicine, said, "Sequencing already assists patient management for a number of conditions such as HIV, but now that it is possible to sequence M. tuberculosis from sputum from suspected multi-drug resistance patients means it has a role in the management of tuberculosis. We have developed a prototype to guide treatment of patients with drug resistant disease, where personalized medicine and treatment offers improved rates of cure."
Complete information regarding the new online tool was published in the May 27, 2015, online edition of the journal Genome Medicine.
Related Links:
TB-Profiler tool
London School of Hygiene & Tropical Medicine
The World Health Organization (WHO) estimated that 5% of the world's 11 million tuberculosis patients have multi-drug-resistance disease (MDR-TB) and that 480,000 new cases arose during 2013 alone. Of those approximately 9% have extensively resistant tuberculosis (XDR-TB) where, in addition to resistance to at least both of the major first line drugs (isoniazid and rifampicin), they also have resistance to two classes of second line drugs used to treat MDR-TB (the fluoroquinolones and the injectable drugs, amikacin, kanamycin, or capreomycin).
Current molecular tests examine limited numbers of mutations in Mycobacterium tuberculosis, the organism that causes TB, and although whole genome sequencing could fully characterize drug resistance, the complexity of data obtained by this technology has restricted their clinical application.
To help solve this problem investigators at the London School of Hygiene & Tropical Medicine (United Kingdom) have created an online tool that analyses and interprets genome sequence data to predict resistance to 11 drugs used for the treatment of TB. Initially, a library (1,325 mutations) predictive of drug resistance for 15 anti-tuberculosis drugs was compiled and then validated for 11 of them using genomic-phenotypic data from 792 strains. A rapid online "TB-Profiler" tool was developed to report drug resistance and strain-type profiles directly from raw sequences. The TB-Profiler tool is available on the Internet (Please see Related Links below).
Senior author Dr. Taane Clark, reader in genetic epidemiology and statistical genomics at the London School of Hygiene & Tropical Medicine, said, "Sequencing already assists patient management for a number of conditions such as HIV, but now that it is possible to sequence M. tuberculosis from sputum from suspected multi-drug resistance patients means it has a role in the management of tuberculosis. We have developed a prototype to guide treatment of patients with drug resistant disease, where personalized medicine and treatment offers improved rates of cure."
Complete information regarding the new online tool was published in the May 27, 2015, online edition of the journal Genome Medicine.
Related Links:
TB-Profiler tool
London School of Hygiene & Tropical Medicine
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia